anti-CD22 IgG conjugated maytansine (Redwood Bioscience)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD22 IgG conjugated maytansine (Redwood Bioscience)

Drug Alias Nameantibody-drug conjugates (Redwood Bioscience)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionCD226 antigen blockers

TargetsCD226 antigen

Therapy Area/IndicationsLymphoma, B-CellLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRedwood Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRedwood Bioscience Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia

Other Information

ATC CodeN/A